Study of Therapeutic Options for Subjects Discontinuing Efalizumab and Experiencing Disease Recurrence

NCT01079988 · clinicaltrials.gov ↗

PHASE4

Phase

COMPLETED

Status

41

Enrollment

INDUSTRY

Sponsor class

Conditions

Psoriasis

Interventions

DRUG: Cyclosporins
DRUG: Retinoids
DRUG: Systemic corticosteroids
DRUG: Methotrexate
DRUG: Systemic corticosteroids/methotrexate

Sponsor

Merck KGaA, Darmstadt, Germany